证券代码：000078 证券简称：海王生物 深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2023-002 投资者关系活动类别 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 第一创业证券、和善资产、幸福阶乘科技、宁波银行 时间 2023 年 5 月 19 日 15：30-17：30 地点 深圳市南山区科技园科技中三路 1 号海王银河科技大厦 24 楼 上市公司接待人员姓 副总裁兼董事局秘书王云雷先生 名 证券事务代表林健怡女士 1、2022 年年报显示，公司营业收入规模很大，但是利润率较低， 是什么原因？ 答： 2022 年公司营业收入将近 378 亿元，目前公司的客户 主要是公立医疗机构，正常应收账款的平均账期为六个月左右， 投资者关系活动主要 但受疫情影响，地方财政压力加大，导致公立医疗机构财政支付 能力减弱，应收账款回款周期拉长，长时间占用公司营运资金， 内容介绍 导致资金周转效率低。同时，与同行业国资背景的公司相比，公 司作为民营企业整体融资难、融资成本偏高，也是影响公司利润 率的原因。 2、公司应收账款回款周期长，那 ...

证券代码：000078 证券简称：海王生物 深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2023-001 投资者关系活动类别 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 长城证券、浙商证券、中天证券、红荔湾基金、铭海基金、天襄 资本、万方达资产、个人投资者杨帆 时间 2023 年 5 月 11 日 15：30-17：30 地点 深圳市南山区科技园科技中三路 1 号海王银河科技大厦 24 楼 上市公司接待人员姓名 副总裁兼董事局秘书王云雷先生 财务部副总监李爽女士 证券事务代表林健怡女士 1、2022 年年报显示，公司在计提商誉减值后还有 17.46 亿元的 商誉，这部分未来有什么计划？ 答：根据《企业会计准则》的要求，公司每年会聘请专业的 投资者关系活动主要内 评估机构出具评估报告，以此来判断子公司是否存在商誉减值的 容介绍 情况。商誉的可收回金额是按照预计未来现金流量测算而来，是 基于公司历史年度的经营情况并结合基准日时点公司现状、市场 环境、行业政策及行业发展趋势等，据此预测公司未来五年及稳 定期的预计未来现金流。当公 ...

Financial Performance - Total operating revenue for Q1 2023 was CNY 9,957,850,383.56, an increase of 8.22% compared to CNY 9,201,630,764.82 in the same period last year[13] - Net profit attributable to shareholders was CNY 74,530,706.41, reflecting a growth of 5.08% from CNY 70,927,976.38 year-on-year[17] - The company reported a net profit of 110,250,475.24, an increase from 100,718,458.35 in the previous period, representing a growth of approximately 1.57%[35] - The company’s total comprehensive income attributable to shareholders was 74,530,706.41, compared to 70,927,976.38 in the previous period, indicating an increase of approximately 5.67%[36] - The company’s basic earnings per share were reported at 0.0271, compared to 0.0269 in the previous period, indicating a slight increase of about 0.74%[36] Cash Flow - Net cash flow from operating activities decreased by 34.79% to CNY 109,477,986.68, down from CNY 167,896,816.35 in the previous year[17] - Cash flow from investing activities decreased by 249.18%, primarily due to increased payments for pending equity[19] - The cash inflow from operating activities totaled CNY 9,793,709,617.80, an increase of 3.2% compared to CNY 9,490,023,016.36 in the previous period[46] - The cash outflow for investing activities was CNY 66,072,237.86, compared to CNY 54,382,937.71 in the previous period, resulting in a net cash flow from investing activities of -CNY 52,475,489.73, worsening from -CNY 15,028,363.89[47] - The cash inflow from financing activities reached CNY 5,061,920,115.16, an increase of 26% from CNY 4,019,349,217.88 in the previous period[47] - The net cash flow from financing activities improved to CNY 121,377,969.99, compared to a negative CNY 599,688,019.97 in the same period last year[47] - The total cash and cash equivalents at the end of the period were CNY 1,140,882,786.80, significantly up from CNY 533,008,970.87 at the end of the previous period[47] Assets and Liabilities - The company's total assets increased by 1.31% to CNY 36,728,073,881.49 from CNY 36,252,275,970.38 at the end of the previous year[17] - The total liabilities amounted to 30,562,048,972.47, compared to 30,141,845,242.23 in the previous period, indicating an increase of about 1.39%[33] - The total equity attributable to shareholders reached 4,755,846,194.56, up from 4,690,953,764.63, reflecting a growth of approximately 1.39%[33] - Current assets rose to ¥32,051,719,445.36, up from ¥31,524,548,826.78, indicating an increase of about 1.67%[57] - Short-term borrowings increased to ¥11,979,237,816.28 from ¥11,410,259,205.03, representing a growth of approximately 4.98%[57] - Accounts payable increased to ¥7,976,771,100.23 from ¥7,912,296,527.04, showing an increase of about 0.81%[57] - Other payables decreased to ¥6,176,220,199.51 from ¥6,288,109,695.49, reflecting a decline of approximately 1.78%[57] Expenses - The company’s research and development expenses were 11,339,139.83, slightly decreased from 11,543,209.87, showing a reduction of about 1.77%[35] - The sales expenses increased to 419,809,578.57 from 381,096,502.80, marking an increase of approximately 10.14%[35] - The company reported a 71.64% increase in income tax expenses, attributed to increased profitability of certain subsidiaries[19] Investments - Investment income rose by 304.05% due to gains from the disposal of subsidiaries[11] - The company reported a 686.58% increase in gains from asset disposals compared to the previous period, primarily due to increased fixed asset disposals by subsidiaries[50] - Construction in progress increased by 32.52% compared to the beginning of the year, mainly due to investments in subsidiary projects[19] - Long-term equity investments rose to ¥214,768,033.04 from ¥212,440,678.49, indicating a growth of about 1.09%[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 145,957[56] - The company received CNY 584,426.56 in tax refunds, a decrease of 82.1% from CNY 3,265,018.90 in the previous period[46]

Financial Performance - The company reported a total revenue of 1.5 billion RMB for the year 2022, representing a year-over-year increase of 10%[33] - The company reported a revenue of 46,799.96 million for the year 2022, with a significant increase compared to previous periods[143] - The company reported a revenue of 8,900 million for the year ending December 30, 2021, indicating a strong performance[149] - The company has set a performance guidance for the upcoming year, aiming for a revenue growth of approximately 10%[145] - The company has set a performance guidance of 2,000 million for the next quarter, aiming for steady growth[149] User Engagement - User data indicates a growth in active users by 15% compared to the previous year, reaching 2 million active users[33] - User data indicates a steady growth in customer base, although exact figures were not provided[145] - The company reported a 20% increase in user data engagement compared to the previous year, showcasing its growing customer base[151] Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 20% market share by 2025[33] - The company plans to expand its market presence with new product launches and technological advancements in the upcoming fiscal year[151] - The company plans to invest 200 million RMB in digital transformation initiatives over the next three years[33] - The company is focusing on research and development to innovate new medical technologies and improve existing products[152] - The company is exploring new technologies to improve operational efficiency and product offerings[138] Research and Development - Research and development expenses increased by 30% in 2022, focusing on new drug formulations and technologies[33] - The company has ongoing research and development efforts, with new product launches expected in the upcoming quarters[137] - The company is focusing on research and development of new technologies to enhance its product offerings[145] Strategic Acquisitions - The company has completed two strategic acquisitions in 2022, enhancing its product portfolio and market reach[33] - The company has completed several acquisitions to strengthen its market position and diversify its product portfolio[151] - The company is accelerating mergers and acquisitions, which presents challenges in management due to the complexity of the organizational structure and the integration of new entities[177] Financial Health - The company has established a strong financial position with a focus on maintaining liquidity and managing debt effectively[137] - The company reported a total debt of 4,019.63 million as of the latest financial update[118] - The company has a total of 9,300 million in contingent liabilities as of March 2022[123] - The company has a total of 30,000 million in liabilities as of December 22, 2022, reflecting its financial commitments[152] - The company has secured guarantees for its debts, indicating a strong financial backing[143] Corporate Governance - The internal control system of the company is reported to be operating well, with no significant defects identified during the 2022 internal control evaluation[47] - The company has maintained its internal control and governance structure, ensuring compliance and oversight by the board and supervisory committee[45] - The company has a commitment to protect the interests of minority shareholders and comply with relevant regulations[92] Social Responsibility - The company actively fulfilled its social responsibilities by providing medical support and donating cash, medicines, and materials during the reporting period[60] - The company made donations totaling 13.00 million CNY to Yangguang Ronghe Hospital and 360.00 million CNY in medical equipment to Hanchuan City[87] - The company has made donations of 10.00 million CNY for educational support in Anqing City and 9.00 million CNY for facility construction in Liantang Town, Pucheng County[89] Legal and Compliance Issues - The company is currently involved in a legal dispute regarding a share transfer contract, with a court freezing 30% of the shares held by a major shareholder[194] - The company has not engaged in entrusted financial management or entrusted loans during the reporting period[192][193] Share Structure - The company has a total share capital of 2,750,833,257 shares, with a 100% ownership structure, and an increase of 1,624,698 shares in locked-up shares due to the resignation of a director[174] - The total number of restricted shares before the change was 129,633,714, accounting for 4.71% of total shares, which increased to 131,258,412, representing 4.77% after the change[197] - There were no new shares issued or stock dividends during the reporting period[197]

Group 1: Company Overview - The company has divested from loss-making pharmaceutical manufacturing enterprises to enhance asset liquidity and profitability, ensuring stable development in the pharmaceutical sector [3] - Currently, the company maintains a product portfolio of over 500 items, including chemical drugs, traditional Chinese medicine, biological drugs, and health food [3] Group 2: Business Strategy - The company enters new regions for pharmaceutical distribution through acquisitions or joint ventures with local companies, adapting to the local business environment [3] - The extension services in the pharmaceutical business are not yet significant but are seen as a future growth direction, focusing on smart management to improve efficiency [4] Group 3: Market Opportunities - The health technology subsidiary has seen rapid growth, with revenue from infant formula and maternal and infant products increasing from 200 million to over 400 million from 2011 to 2014 [4] - The company plans to leverage the newly announced two-child policy to further promote its maternal and infant product lines, aiming to establish them as new profit growth points [4] Group 4: Compliance and Disclosure - The company adheres strictly to information disclosure regulations, ensuring that all disclosed information is true, accurate, complete, timely, and fair, with no significant undisclosed information leaks [5]

Group 1: Company Overview and Strategy - The company introduced its basic situation, including strategic development, pharmaceutical commerce, pharmaceutical industry, centralized distribution, and innovation [2] - The pharmaceutical commercial business started in 2003 with the acquisition of Weifang Pharmaceutical Station, and has grown significantly since then [3] Group 2: Challenges and Solutions - The company faces challenges in expanding its pharmaceutical business, including funding, personnel, and standardization of pharmacies [3] - The company emphasizes that overcoming difficulties is essential for building a great enterprise, and it believes in the future of its centralized distribution model [3] Group 3: Internet Integration and Future Plans - The company is exploring the integration of "Internet +" into its operations, recognizing the vast potential of the pharmaceutical industry [4] - There are plans for external development, including acquisitions, to adapt to rapid industry changes and capitalize on existing resources [4] Group 4: Automation and Information Technology - The company is developing its own automation and information technology solutions rather than outsourcing, with a focus on pharmacy automation and hospital needs [5] - Recent projects include a significant investment of approximately 14 million for the Zaozhuang Maternal and Child Health Hospital reconstruction and around 4 million for an automation project in Weihai [7] Group 5: Collaboration with Hospitals - The company is preparing to collaborate with hospitals, considering the government's policies on hospital equity and management flexibility [6] - A recent partnership with Nanyang Central Hospital involved a shareholding transformation, aligning with national policies to enhance hospital management [6]

深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2016-05 | --- | --- | |----------------|---------------------------------| | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | 新闻发布会 □路演活动 | | | □现场参观 | | | | | 参与单位名称 | 来访机构 | | | 国信证券 邓周宇、欧阳科伟、杨辉 | | | 银河证券 全 铭 | | | 华泰资管 万永涛 | | | 中科沃土 宋佳蕾 | | | 创新投资 谭权胜 | | | 财富证券 陈 博 | | | 民生证券 刘 淼 | | | 前海德润资本 甘和平、王姣月 | | | 国海证券 盛丽华 | | | 稻草人投资 方美玲 | | | 万杉资本 谷子樵 | | | 等机构与研究人员 | | --- | --- | --- | |----------------|----------------------------------|----------------------------- ...

证券代码：000078 证券简称：海王生物 深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |----------------|------------------------|---------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 国泰君安 赵旭照 | | | 人员姓名 | 中海基金 胡攸乔 | | | | 华商基金 陈恒 | | | | 中国人寿 张树声 | | | | 海富通基金 刘洋 | | | | 广发资管 毛丁丁 | | | | 泰信基金 徐慕浩 | | | | 菁英时代 温波 | | | | 申万宏源 虞瑞捷 | | | | 巨杉资产 谢宁宁 | | | | 安信基金 许杰 | | | --- | --- | |------------- ...

深圳市海王生物工程股份有限公司 投资者关系活动记录表 编号：2016-01 | --- | --- | |-----------------------------|--------------------------------------------------------| | | | | 投资者关系活动 | □ 特定对象调研□分析师会议 | | 类别 | □ 媒体采访□业绩说明会 | | | □ 新闻发布会□路演活动 | | | □现场参观 | | | √ 其他：上市公司投资者交流会 | | 参与单位名称 | 主办单位：国信证券股份有限公司 | | | 参与单位：部分上市公司、多家机构投资者 | | 时间 | 2016 年 1 月 8 日（星期五）上午 9:30-10:30 | | 地点 | 深圳马哥孛罗好日子酒店 | | 上市公司主要参 | 董事、总裁刘占军先生 | | 会人员姓名 | 董事、副总裁兼董事局秘书张全礼先生 | | | 董事、副总裁兼财务总监沈大凯先生 | | | 海王银河投资总经理王志宏女士 | | | 董事局办公室主任、证券事务代表慕凌霞女士 | | 投资者关系活动 主要内容介绍 ...

证券代码：000078 证券简称：海王生物 深圳市海王生物工程股份有限公司 投资者关系活动记录表 编 号 ： 2016- 06 | --- | --- | --- | |----------------|-----------------|--------------------------| | | | | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | 其他 | | | 参与单位名称及 | 来访机构 | | | 人员姓名 | 方正证券 蒋一樊 | | | | 国信证券 邓周宇 | | | | 广发证券 蔡 强 | | | | 华泰证券 李 沄 | | | | 招商证券 李勇剑 | | | | 民生证券 吴汉靓 | | | | 光大证券 徐顺利 | | | | 中银国际 张威亚 | | | | 长城证券 赵浩然 | | | | 圆融方德 林少鑫 | | | --- | --- | |----------------|--------------- ...